as 11-15-2024 4:00pm EST
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
Founded: | 2007 | Country: | United States |
Employees: | N/A | City: | SAN DIEGO |
Market Cap: | 7.2M | IPO Year: | N/A |
Target Price: | N/A | AVG Volume (30 days): | 102.4K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.97 | EPS Growth: | N/A |
52 Week Low/High: | $0.32 - $1.74 | Next Earning Date: | 11-26-2024 |
Revenue: | $103,000 | Revenue Growth: | -72.01% |
Revenue Growth (this year): | 59.08% | Revenue Growth (next year): | 18.24% |
ONVO Breaking Stock News: Dive into ONVO Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Zacks Small Cap Research
7 days ago
Associated Press Finance
10 days ago
Zacks Small Cap Research
3 months ago
GlobeNewswire
4 months ago
Zacks Small Cap Research
5 months ago
GlobeNewswire
6 months ago
GlobeNewswire
6 months ago
The information presented on this page, "ONVO Organovo Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.